NVR 3 778

Drug Profile

NVR 3 778

Alternative Names: AL-3778; ALS-003778; JNJ-63595948; NVR-1221; NVR-3-778

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Novira Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in Hepatitis B (In volunteers) in New Zealand (PO, Tablet) (NCT03032536)
  • 31 Jan 2017 Alios Biopharma initiates a phase I trial for Hepatitis B (In volunteers) in New Zealand (PO, Capsule) (NCT03032536)
  • 11 Nov 2016 Updated pharmacokinetics data from phase Ia/Ib trials for Hepatitis B (Monotherapy, Combination therapy) presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top